The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Somatuline Autogel 60 mg, solution for injection in a prefilled syringe



Ipsen Pharmaceuticals LimitedPA0869/004/002

Main Information

Trade NameSomatuline Autogel 60 mg, solution for injection in a prefilled syringe
Active SubstancesLanreotide acetate
Dosage FormSolution for injection in pre-filled syringe
Licence HolderIpsen Pharmaceuticals Limited
Licence NumberPA0869/004/002

Group Information

ATC CodeH01CB Somatostatin and analogues
H01CB03 lanreotide

Status

License statusAuthorised
Licence Issued22/02/2002
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back